Suppr超能文献

一种用于阿片受体μ1(OPRM1)-阿片受体δ1(OPRD1)异源二聚化的激动剂探针的表征

Characterization of an agonist probe for opioid receptor mu 1 (OPRM1)-opioid receptor delta 1 (OPRD1) heterodimerization

作者信息

Pinello Christie, Guerrero Miguel, Eberhart Christina, Volmar Claude-Henry, Saldanha Sanjay A., Cayanan Charmagne, Urbano Mariagela, Brown Steven J, Ferguson Jill, Gomes Ivone, Devi Lakshmi A., Roberts Edward, Hodder Peter, Rosen Hugh

机构信息

The Scripps Research Institute, Jupiter, FL

The Scripps Research Institute, La Jolla, CA

Abstract

Opiates such as morphine are the choice analgesic in the treatment of chronic pain due to their potent and rapid action. Opioid receptors belong to the family of G protein-coupled receptors (GPCRs), one of the largest gene families in the mammalian genome. The OPRM1 gene encodes the mu opioid receptor, which is the primary site of action for morphine and other commonly used opioids such as heroin, fentanyl, and methadone. The long-term use of opiates is limited because of the development of tolerance and dependence, as well as respiratory suppression and constipation. Due to their clinical importance, various strategies have been considered for making opiates more effective while curbing liabilities such as addiction. One such strategy has been to use a combination of drugs to improve the effectiveness of morphine. In particular, delta opioid receptor (OPRD1) ligands have been useful in enhancing morphine’s potency, but the underlying molecular basis is not understood. It has been shown that modulation of receptor function by physical association between OPRM1 and OPRD1 is a potential mechanism; heteromerization of OPRM1 with OPRD1 leads to the modulation of receptor binding and signaling properties. It has further been shown that the selective activation of the OPRM1-OPRD1 heteromer by a combination of OPRM1 agonist with OPRD1 antagonist can be blocked by antibodies that selectively recognize the heteromer. Therefore, the identification of compounds that selectively activate OPRM1-OPRD1 heterodimerization may have potential in the treatment of pain and alleviate unwanted effects associated with opiate use. The Scripps Research Institute Molecular Screening Center (SRIMSC), part of the Molecular Libraries Probe Production Centers Network (MLPCN), reports here an agonist for OPRM1-OPRD1 heterdimerization, ML335, with an EC50 of 403 nM, and selectivities vs. OPRM1, OPRD1, and HTR5A of 37, 2.7, and >99, respectively.

摘要

诸如吗啡之类的阿片类药物因其强效且快速的作用,是治疗慢性疼痛的首选镇痛药。阿片受体属于G蛋白偶联受体(GPCRs)家族,是哺乳动物基因组中最大的基因家族之一。OPRM1基因编码μ阿片受体,它是吗啡以及其他常用阿片类药物(如海洛因、芬太尼和美沙酮)的主要作用位点。由于耐受性和依赖性的产生,以及呼吸抑制和便秘等问题,阿片类药物的长期使用受到限制。鉴于其临床重要性,人们考虑了各种策略来使阿片类药物更有效,同时抑制成瘾等不良反应。其中一种策略是联合使用药物以提高吗啡的疗效。特别是,δ阿片受体(OPRD1)配体在增强吗啡效力方面很有用,但潜在的分子机制尚不清楚。研究表明,OPRM1与OPRD1之间通过物理缔合调节受体功能是一种潜在机制;OPRM1与OPRD1异聚化会导致受体结合和信号特性的调节。进一步研究表明,OPRM1激动剂与OPRD1拮抗剂联合对OPRM1 - OPRD1异聚体的选择性激活可被选择性识别该异聚体的抗体阻断。因此,鉴定选择性激活OPRM1 - OPRD1异二聚化的化合物可能在疼痛治疗中具有潜力,并减轻与阿片类药物使用相关的不良影响。斯克里普斯研究所分子筛选中心(SRIMSC)是分子文库探针生产中心网络(MLPCN)的一部分,在此报告了一种OPRM1 - OPRD1异二聚化激动剂ML335,其半数有效浓度(EC50)为403 nM,对OPRM1、OPRD1和5 - 羟色胺受体5A(HTR5A)的选择性分别为37、2.7和>99。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验